1. Scrip
  2. >>Business
  3. >>Financing

Finance Watch: US Market May Warm To Go-Public Options As Summer Progresses

Renaissance Capital Expects Active July, September

 
• By Mandy Jackson

Public Company Edition: The IPO market in the US cooled in Q2, but a warm-up may come in Q3 alongside new SPAC merger opportunities; Artiva may be the next biopharma firm to go public. Also, IDEAYA and Recursion grossed $302.4m and $200m, respectively, in follow-on offerings.

Finance Watch Public Company
• Source: Alamy

The number of biopharmaceutical company initial public offerings in the US dropped considerably from the first quarter to the second quarter, but with 12 IPOs during the first half of 2024 the market for first-time offerings by drug developers is on track to meet or slightly exceed 2023, when 21 biopharma firms went public in the US, if the pace of new offerings holds steady in the second half of this year.

Evaluate Pharma tracked three IPOs globally in Q2, down sharply from nine in Q1. (Also see "IPOs Collapse In...

More from Financing

More from Business

Syncona Looks To Go Private As Market Decline Deepens

 
• By Andrew McConaghie

While some are calling for Syncona to be wound up, the UK-based company believes many existing and new investors will back the creation of new private fund.

ASCO: Pushing The Frontiers Of ADCs

 
• By Mary Jo Laffler

Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.

Top 10 Drugs Q1 2025: Keytruda Dominates; Mounjaro Climbs

 
• By Eleanor Malone

Lilly’s Mounjaro for diabetes rose from sixth to third position among the top-selling drugs in the first quarter of 2025, Rival Ozempic retained second position and Merck & Co’s immuno-oncology blockbuster Keytruda stayed far ahead.